Institution identification

PURI

https://redirect.ema.europa.eu/resource/50154

Institution ID

50154

Institution full name and acronym

Fundació Institut Universitari per a la Recerca a l'Atenció Primària de Salut Jordi Gol i Gurina, IDIAPJGol

Institution countries

Spain

Type of institution

Educational Institution
Laboratory/Research/Testing facility
Not-for-profit

Institution role

Data provider
Researcher

Institution website

ENCePP partner

Yes
Institution description
The Jordi Gol Foundation was created in 1995 under the auspices of the Catalan Health Institute. Since its inception it has pioneered research in Primary Health Care in Spain.In 2006 the Foundation becomes the Primary Health Care University Research Institute Jordi Gol (IDIAP Jordi Gol). The IDIAP aims to generate new knowledge and practical evidence to promote,advance and manage Primary Care research in Catalonia and other areas,by means of training,dissemination of results and translation of research findings into clinical practice.IDIAP Jordi Gol has at present 107 active competitve projects and 51 clinical trials. It has the Medicines Research Unit that leads different studies adn clinical trials and the SIDIAP database (www.sidiap.org) with clinical data on 5.8 million of inhabitants.
Institution details
Experience with collecting data directly from individual patients or respondents:
Yes
Interest in carrying out research that is funded by pharmaceutical companies:
Yes

Contact

Studies conducted by the institution

A post-authorisation/post-marketing observational study to evaluate the association between exposure to AZD1222 and safety concerns using existing secondary health data sources (COVID-19)
A Retrospective Cohort Study to Assess Drug Utilisation and Long-Term Safety of Galcanezumab in European Patients in the Course of Routine Clinical Care (I5Q-MC-B002)
ACCESS template protocol for safety of COVID-19 vaccines
ADVANCE POC I Risk pillar - Testing new approaches to monitoring benefit/risk with pertussis vaccines as test case: Incidence rates of safety outcomes of whole-cell pertussis and acellular pertussis vaccines in pre-school children
ADVANCE POC Study Protocol - Testing new approaches to monitoring benefit/risk with pertussis vaccines as test case. Coverage rates of acellular and whole-cell pertussis-containing vaccines in preschool children (ADVANCE Coverage POC)
An Observational Post-Authorisation Safety Study of Lesinurad Patients (SATURATES)
An Observational Post-Authorization Safety Study to Assess the Safety of Ad26.COV2.S Using European Healthcare Data through VAC4EU (COVID-19)
Apixaban drug utilization study in Stroke prevention in atrial fibrillation (SPAF)
Assessing exposure to cardiovascular therapy, anxiety depressive syndrome treatment and anti-infectives during pregnancy and breastfeeding (Drug exposure in pregnancy and breastfeeding)
ASSOCIATION BETWEEN THROMBOSIS WITH THROMBOCYTOPENIA SYNDROME (TTS) OR THROMBOEMBOLIC EVENTS, AND COVID-19 VACCINES
Cilostazol Drug Utilisation Study
Comparative safety study of tramadol and codeine users: a population-based cohort study
Cost-Effectiveness Analysis of Treatment with Statins in Primary Prevention of Vascular Events (EPREV project)
DARWIN EU® - Background rates of serious adverse events to contextualise safety assessments in clinical trials and non-interventional studies in adolescent and adult patients with severe asthma
DARWIN EU® Drug utilisation of valproate-containing medicinal products in women of childbearing potential
DARWIN EU® Drug utilisation study of medicines with prokinetic properties in children and adults diagnosed with gastroparesis
DARWIN EU® DUS of Antibiotics in the ‘Watch’ category of the WHO AWaRe classification of antibiotics for evaluation and monitoring of use
DARWIN EU® EHDS Use Case: Natural history of coagulopathy in COVID-19 patients and persons vaccinated against SARS-CoV-2 in the context of the OMICRON variant
DARWIN EU® Monitoring prescription of medicines for public health emergencies at risk of shortages
DARWIN EU® Multiple myeloma: patient characterisation, treatments and survival in the period 2012-2022
DARWIN EU® Natural history of dermatomyositis (DM) and polymyositis (PM) in adults and paediatric populations
DARWIN EU® Prevalence of rare blood cancers in Europe
DARWIN EU® Rates of occurrence of treatment-related intercurrent events in patients with major depressive disorder
DARWIN EU® Treatment patterns of drugs used in adult and paediatric population with systemic lupus erythematosus
DARWIN EU® Use of take-home naloxone for opioid overdose treatment
DARWIN EU® – Frailty and polypharmacy among adults with selected cancers at the time of diagnosis
Drug Utilization Study Evaluating Additional Risk Minimization Measures for Upadacitinib in the Treatment of Atopic Dermatitis in Europe
Drug utilization study of mirabegron (Betmiga®) using real-world healthcare databases from the Netherlands, Spain, United Kingdom and Finland (Mirabegron DUS)
Effectiveness of an Interventional to Improve the Adequacy of the Indication of Lipid Lowering Treatment in Primary Prevention: Randomized Clinical Trial (Adequacy of Lipid Treatment)
EMIF Use Case 17 - Investigating the relationship in paediatric population between dosing of antibiotics (prescribed, dispensed or administered) and patient’s weight. (EMIF UC17)
Estimating prevalence and incidence of acute myocardial infarction in a set of heterogeneous sources of observational health data collaborating in the EMIF Platform
EUROPEAN NON-INTERVENTIONAL POST AUTHORIZATION SAFETY STUDY RELATED TO SERIOUS INFECTIONS FOR ROMOSOZUMAB BY THE EU ADR ALLIANCE
EUROPEAN NON-INTERVENTIONAL POST-AUTHORIZATION SAFETY STUDY RELATED TO ADHERENCE TO THE RISK MINIMIZATION MEASURES FOR ROMOSOZUMAB BY THE EU-ADR ALLIANCE
European non-interventional post-authorization safety study related to serious cardiovascular events of myocardial infarction and stroke, and all-cause mortality for romosozumab by the EU-ADR Alliance
European Program of Post-Authorization Safety Studies for Protelos®/Osseor® through EU-ADR Alliance
Exposure and coverage to routine schedule vaccines in different EU countries (ADVANCE-POC2)
Hydroxychloroquine safety and potential efficacy as an antiviral prophylaxis in light of potential wide-spread use in COVID-19: a multinational, large-scale network
cohort and self-controlled case series study
Impact of medication adherence on mortality and cardiovascular morbidity: a population-based retrospective cohort study. IMPACT study
Linaclotide Safety Study for the Assessment of Diarrhoea—Complications and Associated Risk Factors in Selected European Populations with IBS-C
Linaclotide Utilisation Study in Selected European Populations
Management of Urinary Tract Infections in Catalonia: adequacy of diagnostic and therapeutic management, predictors of complications and impact of suppressive therapies on the severity of potentially serious infections (PROJECT ITUCAT)
Measurement of the effectiveness of statins in vascular morbidity and mortality reduction in the population without history of vascular disease but with intermediate risk and ankle-brachial Index < 0.9 in primary care setting (MARIA study)
Monitoring safety of Spikevax in pregnancy: an observational study using routinely collected health data in five European countries (COVID-19)
mRNA-1273-P910: Clinical course, outcomes and risk factors of myocarditis and pericarditis following administration of Moderna vaccines targeting SARS-CoV-2.
Multinational, multi-database drug utilization study of indacaterol/glycopyrronium bromide in Europe
Non-interventional post-authorization multi-database safety study to assess the risk of myotoxicity, hepatotoxicity and acute pancreatitis in statin-exposed heart failure patients with or without concomitant use of sacubitril/valsartan (Entresto®)
Non-interventional post-authorization multi-database safety study to characterize the risk of angioedema and other specific safety events of interest in association with use of Entresto® (sacubitril/valsartan) in adult patients with heart failure
Opioid drug utilization and comparative safety: a population-based cohort study
Post-Authorisation Safety Study of Agomelatine and the Risk of Hospitalisation for Acute Liver Injury
Post-Authorization Active Surveillance Safety Study Using Secondary Data to Monitor Real-World Safety of Spikevax in Europe (COVID-19)
Project Sc(y)lla: SARS-Cov-2 Large-scale Longitudinal Analyses on the comparative safety and effectiveness of treatments under evaluation for COVID-19 across an international observational data network
Ranitidine and other histamine H2-receptor antagonists – a drug utilisation study
Rapid Safety Assessment of SARS-CoV-2 vaccines in EU Member States using electronic health care datasources (CVM Covid19-Vaccine-Monitor-EHR)
Riesgo de accidente vascular cerebral asociado al uso de medicamentos: estudio de casos y controles (IJG-AVC-2015)
Riesgo de cáncer colorrectal asociado al uso de medicamentos: estudio de casos y controles (IJG-CCR-2015)
Risk of lactic acidosis associated with metformin use in patients with type 2 diabetes and moderate-severe chronic kidney disease: a case-control study (ALIMAR-C2)
Risks of pharmacological interactions of direct oral anticoagulants: thrombotic and hemorrhagic events leading to hospital admission in Catalonia. (IFACOD)
Safety of Paxlovid Among Patients with Moderate or Severe Hepatic or Renal Impairment
Safety of Paxlovid During Pregnancy
SAFETY-VAC: a framework for the post-authorisation safety monitoring and evaluation of vaccines in the European Union (SAFETY-VAC)
SAFETY-VAC: Background incidence estimation of flares of pre-existing chronic diseases using pan-European electronic healthcare data sources. (SAFETY VAC)
Sociodemographic, clinical and pharmacological characteristics associated with the prognosis of patients with SARS-CoV-2 infection (Características sociodemográficas, clínicas y farmacológicas asociadas con el pronóstico en pacientes con infección por SARS-CoV-2)
Study about the results of the addition of a sulfonylurea, DPP4 inhibitors or SGLT2 inhibitors as a second antidiabetic drug in patients with diabetes mellitus type 2 in treatment with metformin and insufficient glycemic control. (eControl Met +)
Study of exposure and use patterns of alternatives to ranitidine-containing medicines in patients treated with ranitidine (Ranitidine)
Testing new approaches to monitoring benefit/risk with pertussis vaccines as test case: Incidence rates of pertussis and pertussis related outcomes of whole-cell pertussis and acellular pertussis vaccines in pre-school children (benefit study on pertussis vaccination)
The comparative safety of first-line conventional synthetic disease-modifying anti-rheumatic drugs (csDMARDs) used for the treatment of rheumatoid arthritis: protocol for a multi-database real-world cohort study
The risk of musculoskeletal adverse outcomes after treatment with endocrine blocking treatments for breast cancer (MSKAI)
The utilisation of antiepileptics in men and women of childbearing age, and pregnant women in Europe (ADEPT)
USE OF PSYCHOTROPIC DRUGS IN CHILDREN AND ADOLESCENTS IN CATALONIA. A cohort study with real world data from the electronic primary health care record from 2007-2017. (PEPSICAT)
Uso de fármacos en mujeres embarazadas y lactantes. Consecuencias en la salud de estas mujeres y en la de su descendencia (Drug use in pregnant and breastfeeding women. Outcomes in the health of the women and the offspring) (Drug use during pregnancy and breastfeeding)
Utilisation disease-modifying anti-rheumatic drugs (DMARDs) used for the treatment of rheumatoid arthritis: protocol for a multi-database real-world cohort study
Utilization of antidementia treatments: a large multinational-network population-based study.
VALIDATION STUDY PROTOCOL (OP0007) FOR THE EUROPEAN NON-INTERVENTIONAL POST- AUTHORIZATION SAFETY STUDY RELATED TO SERIOUS CARDIOVASCULAR EVENTS OF MYOCARDIAL INFARCTION AND STROKE AND ALL-CAUSE MORTALITY FOR ROMOSOZUMAB BY THE EU-ADR ALLIANCE (OP0004) AND EUROPEAN NON-INTERVENTIONAL POST-AUTHORIZATION SAFETY STUDY RELATED TO SERIOUS INFECTIONS FOR ROMOSOZUMAB BY THE EU-ADR ALLIANCE (OP0006)